Date and Time: The meeting will be held on September 20, 2011, from 1 p.m. to approximately 4 p.m.

Location: National Institutes of Health (NIH), 9000 Rockville Pike, Building 29B, Conference Room C, Bethesda, MD 20892. The public is welcome to attend the meeting at the specified location where a speakerphone will be provided. Public participation in the meeting is limited to the use of the speakerphone in the conference room. Important information about transportation and directions to the NIH campus, parking, and security procedures is available on the Internet at *http://www.nih.gov/about/visitor/index.htm.* (FDA has verified the Web site address, but FDA is not responsible for any subsequent changes to the Web site after this document publishes in the **Federal Register**.) Visitors must show two forms of identification, one of which must be a government-issued photo identification such as a Federal employee badge, driver's license, passport, green card, etc. Detailed information about security procedures is located at *http://www.nih.gov/about/visitorsecurity.htm.* Due to the limited available parking visitors are encouraged to use public transportation.

Agenda: On September 20, 2011, the committee will meet in open session to hear updates of the research programs in the Laboratory of Enteric and Sexually Transmitted Diseases, Division of Bacterial, Parasitic, and Allergenic Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, FDA.

Procedure: On September 20, 2011, from 1 p.m. to approximately 3:30 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before September 13, 2011. Oral presentations from the public will be scheduled between approximately 2:30 p.m. and 3:30 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before September 9, 2011. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by September 10, 2011.

Closed Committee Deliberations: On September 20, 2011, from approximately 3:30 p.m. to approximately 4 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The committee will discuss the report of the intramural research programs and make recommendations regarding personnel staffing decisions.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

Dated: August 18, 2011.

Jill Hartzler Warner,

Acting Associate Commissioner for Special Medical Programs.

[FR Doc. 2011–21535 Filed 8–22–11; 8:45 am]

BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2011–N–0332]

Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments; Availability; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice of availability that appeared in the **Federal Register** of August 4, 2011 (76 FR 47211). The Agency is required to report annually in the **Federal Register** on the status of postmarketing requirements and commitments required of, or agreed upon by, holders of approved drug and biological products. The August 4, 2011, notice is the Agency's report on the status of the studies and clinical trials that applicants have agreed to, or are required to, conduct. The document was published with an error. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Joyce A. Strong, Office of Policy and Planning, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3208, Silver Spring, MD 20993–0002, 301–796–9148.

SUPPLEMENTARY INFORMATION: In FR Doc. 2011–19806, appearing on page 47211 in the **Federal Register** of August 4, 2011, the following correction is made:

On page 47214, table 1 is corrected to read as follows:

TABLE 1—SUMMARY OF POSTMARKETING REQUIREMENTS AND COMMITMENTS

[Numbers as of September 30, 2010]

	NDA/ANDA (% of Total PMR or % of total PMC)	BLA (% of Total PMR or % of total PMC) [1]
Number of open PMRs	526	149.
On-schedule open PMRs (see table 2 of this document)	477 (91%)	131 (88%).
Off-schedule open PMRs (see table 3 of this document)	49 (9%)	18 (12%).
Number of open PMCs [2]	473	307.
On-schedule open PMCs (see table 4 of this document)	399 (84%)	236 (77%).
Off-schedule open PMCs (see table 5 of this document)	74 (16%)	71 (23%).

[1] On October 1, 2003, FDA completed a consolidation of certain therapeutic products formerly regulated by CBER into CDER. Consequently, CDER now reviews many BLAs. Fiscal year statistics for postmarketing requirements and commitments for BLAs reviewed by CDER are included in BLA totals in this table.

[2] The number of PMCs reported as open as of September 30, 2009, in the ''Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments'' notice published in the **Federal Register** on November 9, 2010 (75 FR 68802), inadvertently also included open PMRs. That error has been corrected for the current reporting period.

Dated: August 17, 2011.

Leslie Kux,

Acting Assistant Commissioner for Policy.

[FR Doc. 2011–21487 Filed 8–22–11; 8:45 am]

BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

2011 Technology Transfer Summit North America Conference

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice of Conference.

SUMMARY: The NIH Office of Technology Transfer extends invitations to attend the 2011 Technology Transfer Summit North America Conference.

DATES: October 3–4, 2011.

ADDRESSES: NIH campus, 9000 Rockville Pike, Bethesda MD, NIH Clinical Center (Building 10), Masur Auditorium.

SUPPLEMENTARY INFORMATION: The NIH campus in Bethesda, MD will be the site for the 2011 Tech Transfer Summit North America (TTSNA), the leading early-stage biotech partnering, licensing, venture and innovation platform, co-hosted and co-sponsored by the NIH Office of Technology Transfer, TTS Ltd. and regional host partners such as BIO Maryland.

TTSNA is one of a series of summits held within the Global Tech Transfer Initiative and is designed specifically to put innovators, early-stage SMEs and technology managers from leading universities and research institutes together with biotech & pharma licensing & business development executives, VCs, serial entrepreneurs, and leading IP specialists for interactive sessions relating to partnering, licensing & business development.

Conference speakers for the 2011 include:

—Kathy Hudson, Deputy Director, National Institutes of Health (NIH)

—James C. Greenwood, President & CEO, BIO

—Shiv Krishnan, Director, Scouting & Partnering, Sanofi, USA

—Sanjeev Munshi, Director, Licensing and External Research, Merck & Co

—David Kaslow, Head of Vaccines Project & Pipeline Leadership, Merck & Co

—Ed Mascioli, Head of Orphan & Genetic Diseases Research Unit, Pfizer

—Arthur Tzianabos, Vice President of Research, HGT Division, Shire

—Steve Groft, Director, Office of Rare Diseases Research, NIH

—Phil Ross, Managing Director, Healthcare, JPMorgan

—Maarten deJong, Managing Director, Barclays Capital

—Andrew Robertson, Chief Policy Officer, BIO Ventures for Global Health

—Orin Herskowitz, Executive Director & Vice President, Intellectual Property Technology Transfer, Columbia Technology Ventures

—Erik Lium, Assistant Vice Chancellor of Research, UCSF

—Brian Kelly, Director, Technology, Enterprise & Commercialisation, Weill Cornell Medical College

—Daniel Perez, Partner, Bay City Capital

—Hubert Birner, Partner, TVM Capital

—Glen Steinbach, COO, Johns Hopkins Technology Transfer

—Markus Goebel, Managing Director, Novartis Venture Fund

The Summit will strive to induce interactive debate, deliberation and discussion, networking and business over the 2-day period with the leaders in the sector. The Summit conference will be further enhanced by the TTS Initiative Business Social Network, an online business-networking platform powered by JuJaMa. The Network is a communication tool for business that will allow the posting of profiles and technology offers; the searching of other participants by category, by technology or licensing offer; and the setting up of meetings prior to, during and after the Summit. Total participation numbers for this conference will be strictly limited to ensure the ideal environment for real discussion and business.

FOR FURTHER INFORMATION CONTACT: More details about the conference including registration information and the conference agenda can be found by contacting Tech Transfer Summit North America (*http://www.techtransfersummit.com/northamerica2011*). Attendees may also enter the Partner Code ''NIH11'' to register with a 10% reduction. For information about sign language interpretation or accommodation for disabilities, please contact Sharon Fields at telephone 301–594–7700 or *fieldssh@od.nih.gov.*

Dated: August 16, 2011.

Steven M. Ferguson,

Deputy Director, Licensing & Entrepreneurship, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2011–21514 Filed 8–22–11; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Targeting Resistance in Select Gram-Negative Pathogens.

Date: September 22–23, 2011.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Hilton Silver Spring, 8727 Colesville Road, Chesapeake Room, Silver Spring, MD 20910.

Contact Person: Nancy Lewis Ernst, PhD, Scientific Review Official, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892–7616, 301–451–7383, *nancy.ernst@nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: August 17, 2011.

Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–21512 Filed 8–22–11; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the